Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Barry Uretsky to Infusions, Intravenous

This is a "connection" page, showing publications Barry Uretsky has written about Infusions, Intravenous.

 
Connection Strength
  
 
 
0.108
  
  1. Huang MH, Wu Y, Nguyen V, Rastogi S, McConnell BK, Wijaya C, Uretsky BF, Poh KK, Tan HC, Fujise K. Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion. Cardiovasc Drugs Ther. 2011 Jun; 25(3):223-32.
    View in: PubMed
    Score: 0.022
  2. Schulman DS, Herman BA, Ziady G, Edwards T, Kormos R, Reddy PS, Follansbee WP, Uretsky BF. Effects of acute alterations in left ventricular loading conditions on peak filling rate in the denervated (transplanted) ventricle. Am J Cardiol. 1991 May 15; 67(13):1103-9.
    View in: PubMed
    Score: 0.022
  3. Uretsky BF, Verbalis JG, Murali S, Betschart AR, Kolesar JA, Reddy PS. Control of atrial natriuretic peptide secretion in patients with severe congestive heart failure. J Clin Endocrinol Metab. 1990 Jul; 71(1):146-51.
    View in: PubMed
    Score: 0.021
  4. O'Connor CM, Gattis WA, Uretsky BF, Adams KF, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999 Jul; 138(1 Pt 1):78-86.
    View in: PubMed
    Score: 0.010
  5. Lo MW, Toh J, Emmert SE, Ritter MA, Furtek CI, Lu H, Colucci WS, Uretsky BF, Rucinska E. Pharmacokinetics of intravenous and oral losartan in patients with heart failure. J Clin Pharmacol. 1998 Jun; 38(6):525-32.
    View in: PubMed
    Score: 0.009
  6. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE, Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997 Jul; 134(1):44-54.
    View in: PubMed
    Score: 0.009
  7. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, J?bsis MM, Blackburn SD, Shortino D, Crow JW. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 01; 334(5):296-301.
    View in: PubMed
    Score: 0.008
  8. Sueta CA, Gheorghiade M, Adams KF, Bourge RC, Murali S, Uretsky BF, Pritzker MR, McGoon MD, Butman SM, Grossman SH, et al. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. Am J Cardiol. 1995 Jan 19; 75(3):34A-43A.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.